Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LSS | P48449 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | F11 | P03951 | 2/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 4/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10224428 | 0.86 | FGFR3 (0.34) | L3MBTL1KDRFGFR3 | |
| SCHEMBL11925794 | 0.83 | L3MBTL1 (0.41) | L3MBTL1F2F11PRSS1PRSS2 | |
| SCHEMBL11925795 | 0.81 | L3MBTL1 (0.39) | L3MBTL1SMN1; SMN2KDRFGFR3 | |
| SCHEMBL15693723 | 0.81 | L3MBTL1 (0.39) | L3MBTL1F2F11PRSS1PRSS2 | |
| SCHEMBL73204 | 0.79 | L3MBTL1 (0.50) | L3MBTL1KDRFGFR3PDGFRBROCK1 | |
| SCHEMBL10174975 | 0.79 | MEN1 (0.47) | L3MBTL1SMN1; SMN2KDRFGFR3PDGFRB | |
| SCHEMBL15567289 | 0.78 | L3MBTL1 (0.48) | L3MBTL1F2F11PRSS1PRSS2 | |
| SCHEMBL600503 | 0.78 | FGFR4 (0.43) | L3MBTL1F2PRSS1SMN1; SMN2KDR | |
| SCHEMBL3319893 | 0.78 | L3MBTL1 (0.52) | L3MBTL1KDRFGFR3PDGFRB | |
| SCHEMBL10225519 | 0.77 | L3MBTL1 (0.41) | L3MBTL1LSSSMN1; SMN2KDRFGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722687-B2 | Imidazo [1,2-A]pyridine derivatives as FGFR kinase inhibitors for use in therapy | ASTEX THERAPEUTICS LTD (GB) | 2014-05-13 | — | — | US | disclosed |
| US-20120041000-A1 | IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041000-A1 | IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY | FGFR1, FGFR3, FGFR2 | L3MBTL1 4220/4885LSS 4082/4885F2 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.